Core Insights - Crystal Tech Holdings (02228.HK) announced a strategic partnership with Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] - The partnership grants Eli Lilly access to Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis technologies [1] - The collaboration includes upfront and milestone payments totaling several tens of millions of USD, with potential total milestone payments reaching up to $345 million [1] Company Overview - Ailux Shanghai, a wholly-owned subsidiary of Crystal Tech Holdings, focuses on developing advanced biotherapies using AI-driven solutions [2] - The company has assembled a global team of over 100 members and actively collaborates with leading biopharmaceutical companies to translate cutting-edge scientific achievements into transformative drugs [2] - Crystal Tech Holdings was founded in 2015 by three MIT physicists and operates as an innovative R&D platform leveraging quantum physics, AI, and robotics [2] Financial Performance - In the first half of the year, Crystal Tech Holdings reported a revenue increase of 404% year-on-year, reaching 517 million RMB, with an adjusted net profit of 141 million RMB [3] - Historical revenue figures for Crystal Tech show 62.8 million RMB in 2021, 133 million RMB in 2022, and 80 million RMB in 2023, while net losses were 2.137 billion RMB, 1.439 billion RMB, and 1.906 billion RMB respectively during the same period [3] - The company has raised over 5 billion RMB through eight rounds of financing prior to its IPO, with notable investors including Tencent, Sequoia China, and SoftBank Vision Fund [3] Market Performance - Crystal Tech Holdings has a current market capitalization of 46.26 billion HKD, with a year-to-date increase of nearly 80% [4]
晶泰控股与礼来在双抗领域达成研发合作